Biochemotherapy of metastatic malignant melanoma. Predictive value of tumour-infiltrating lymphocytes

British Journal of Cancer

Volumn 85, Issue 12, 2001, Pages 1871-1877

  Hakansson A ^a   Gustafsson, B ^a   Krysander, L ^a   Hjelmqvist, B ^b   Rettrup, B ^b   Hakansson L ^a  

^a LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^b KALMAR COUNTY HOSPITAL   (Sweden)

Author keywords

Biochemotherapy; Malignant melanoma; Prediction of response; Tumour infiltrating lymphocytes (TILs)

Indexed keywords

ALPHA INTERFERON; CISPLATIN; DACARBAZINE; OKT 4;

ADULT; AGED; ARTICLE; ASPIRATION BIOPSY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; COST BENEFIT ANALYSIS; DISEASE SEVERITY; FEMALE; HEALTH CARE COST; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPHOCYTE COUNT; MALE; MELANOMA; PREDICTION; PRIORITY JOURNAL; SIDE EFFECT; SURVIVAL TIME; T LYMPHOCYTE; TREATMENT OUTCOME; TUMOR ASSOCIATED LEUKOCYTE;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; BIOLOGICAL RESPONSE MODIFIERS; BIOPSY, NEEDLE; CD4-POSITIVE T-LYMPHOCYTES; CISPLATIN; COMBINED MODALITY THERAPY; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOTHERAPY; INTERFERON ALFA-2B; LIFE TABLES; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MELANOMA; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0035555906     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1054/bjoc.2001.2169     Document Type: Article

References (34)

1. Regulation of monocyte derived interleukin 1 receptor antagonist by cisplatinum
2. A multifactorial analysis of melanoma: Prognostic histopathological features comparing Clark's and Breslow's staging methods
3. Model predicting survival in stage I melanoma based on tumour progression
4. Prognostic value of tumour infiltrating-lymphocytes in the vertical growth phase of primary cutaneous melanoma
5. Randomised trial of interferon α-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases
6. + T cells
7. Tumour thickness and lymphocytic infiltration in malignant melanoma of the head and neck
8. Tumour-infiltrating lymphocytes in patients with metastatic melanoma receiving chemoimmunotherapy
9. Chemotherapy for metastatic melanoma
10. Tumour-infiltrating lymphocytes in metastatic malignant melanoma and response to interferon-alpha treatment
11. Effect of interferon-α on tumour-infiltrating mononuclear cells and regressive changes in metastatic malignant melanoma
12. On down-regulation of the immune response to metastatic malignant melanoma
13. Histologic regression in malignant melanoma: An interobserver concordance study
14. Results of interleukin-2-based treatment in advanced melanoma: A case record-based analysis of 631 patients
15. Sequential chemoimmunotherapy with cisplatin, interleukin-2, and interferon alfa-2a for metastatic malignant melanoma
16. Interferon alpha-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group trial EST 1648
17. High-and low-dose interferon alfa-2b in high-risk melanoma: First analysis of intergroup Trial E1690/S9111/C9190
18. A retrospective histological study of 669 cases of primary cutaneous malignant melanoma in clinical stage I
19. A prospective evaluation of a triple drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) for metastatic melanoma
20. Durable complete responses in metastatic melanoma treated with interleukin-2 in combination with interferon alfa and chemotherapy
21. Effective combination chemo/hormonal therapy for malignant melanoma: Experience with three consecutive trials
22. Spontaneous regression of melanoma
23. Tumour-infiltrating lymphocytes in lymph node melanoma metastases: A histopathologic prognostic indicator and an expression of local immune response
24. Sensitization of human bladder cancer cells to Fas-mediated cytotoxicity by cis-diamminedichloroplatinum
25. Adjuvant interferon α-2a treatment in resected primary stage II cutaneous melanoma
26. Long-term outcome of treatment with dacarbazine, cisplatin, interferon-α and intravenous high dose interleukin-2 in poor risk melanoma patients
27. Combination chemotherapy with interleukin-2 and interferon alfa for the treatment of metastatic melanoma
28. Thin malignant melanomas with regression and metastases
29. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon-alpha 2b
30. Clinical responses and lymphoid infiltrates in metastatic melanoma following treatment with intralesional GM-CSF
31. Partial regression in thin primary cutaneous malignant melanomas clinical stage I
32. Immunocytochemical analysis of the cellular infiltrate in primary regressing and non-regressing malignant melanoma
33. CD4 T cells kill melanoma cells by mechanisms that are independent of Fas (CD95)
34. Tumour metastasis biopsy as a surrogate marker of response to melanoma immunotherapy